Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NKp46 is a crucial activating receptor on natural killer (NK) cells, facilitating the lysis of tumor and virus-infected cells by binding specific ligands. It consists of two C2-type Ig-like domains and plays a significant role in antitumor immunity and responses to viral infections. This receptor is part of the immunoglobulin superfamily and lacks an intrinsic ITAM but transduces signals by associating with ITAM-containing adapters. NKp46 is expressed on NK cells and certain subsets of innate lymphoid cells and T cells, contributing to both innate and adaptive immunity. Its role in recognizing and killing target cells makes it a significant component in cancer and infection therapies.
NKp46 activates NK cell activity through association with ITAM-containing signaling molecules like CD3ζ or FcRγ, leading to the phosphorylation of tyrosine residues and subsequent signal transduction[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural killer cell-activating receptor NKp46 (NKp46).